Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$67.23 USD

67.23
11,849,108

-2.13 (-3.07%)

Updated Sep 17, 2024 04:00 PM ET

After-Market: $67.23 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Tracey Ryniec headshot

Bull of the Day: Edwards Lifesciences (EW)

This medical innovator is a superstar stock.

Mark Vickery headshot

Top Analyst Reports for Apple, Comcast & NVIDIA

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Comcast Corporation (CMCSA) and NVIDIA Corporation (NVDA).

Edwards Lifesciences (EW) Recalls PASCAL's Guide Sheath

Edwards Lifesciences (EW) issues a product recall for its guide sheath based on report from its urgent field safety notice.

Sanghamitra Saha headshot

Top & Flop ETFs of Last Week

Cocoa ETF was a hot trade last week while cannabis ETF lost the most.

Haemonetics (HAE) Grows on New Products, Robust Plasma Sales

Haemonetics (HAE) witnesses a steady uptick in Plasma franchise, fueled by favorable price, volume and mix.

Will Edwards Lifesciences (EW) Gain on Rising Earnings Estimates?

Edwards Lifesciences (EW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Is Edwards Lifesciences (EW) a Solid Growth Stock? 3 Reasons to Think " Yes "

Edwards Lifesciences (EW) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Penumbra's (PEN) Q3 Earnings & Revenues Surpass Estimates

Penumbra (PEN) witnessed strong growth across all geographies and product lines in Q3.

Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?

Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

DexCom (DXCM) Soars to 52-Week High, Time to Cash Out?

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Nevro (NVRO) Q3 Loss Narrower Than Expected, Revenues Up Y/Y

Nevro (NVRO) launches the Senza Omnia SCS System commercially in the United States in Q3.

DexCom (DXCM) Earnings and Revenues Beat Estimates in Q3

DexCom's (DXCM) Q3 earnings benefit from higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook. However, contraction in gross margin remains a woe.

Glaukos (GKOS) Q3 Loss Narrower Than Expected, '19 View Up

Glaukos' (GKOS) Q3 revenues surge year over year. Also, the company raises 2019 revenue guidance.

LHC Group (LHCG) Q3 Earnings Surpass Estimates, Revenues Lag

LHC Group (LHCG) third-quarter results benefit from home health and hospice admissions and higher revenues.

Option Care Health (BIOS) Q3 Earnings Meet, Revenues Top

Albeit Option Care Health (BIOS) is yet to reap material benefits from its merger-related synergies, the reporting of a positive gross margin in third-quarter results is encouraging for investors.

DENTSPLY SIRONA (XRAY) Beats on Q3 Earnings, Ups '19 View

DENTSPLY SIRONA (XRAY) gains from solid segmental contributions in Q3.

Cardinal Health (CAH) Q1 Earnings & Revenues Beat Estimates

Cardinal Health (CAH) Q1 results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.

AmerisourceBergen (ABC) Q4 Earnings & Revenues Beat Estimates

AmerisourceBergen's (ABC) Q4 earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.

Insulet (PODD) Beats on Q3 Earnings, Ups '19 Revenue View

Insulet's (PODD) year-over-year improvement in Q3 revenues on the solid uptake of Omnipod system both in the United States and across international markets looks promising.

OPKO Health (OPK) Q3 Earnings Miss Estimates, Revenues Beat

OPKO Health (OPK) third-quarter results benefit from higher Product revenues and RAYALDEE prescription growth.

CVS Health (CVS) Beats on Q3 Earnings, Raises '19 EPS Guidance

CVS Health's (CVS) strong year-over-year growth in the top line is aided by a robust performance at the Pharmacy Services segment.

HMS Holdings (HMSY) Q3 Earnings Top Estimates, Revenues Miss

HMS Holdings' (HMSY) Q3 earnings benefit from higher revenues at Analytical Services unit and strong 2019 outlook.

Avanos (AVNS) Earnings and Revenues Miss Estimates in Q3

Avanos (AVNS) third-quarter results benefit from higher revenues and strong segmental performance.

Inogen's (INGN) Q3 Earnings and Revenues Beat Estimates

Softness in domestic and international business-to-business revenues impact Inogen's (INGN) Q3 results.

DaVita (DVA) Earnings and Revenues Beat Estimates in Q3

DaVita (DVA) raises guidance for 2019 following impressive Q3 results.